{
  "docId": "019de072-e6c6-771e-b24a-5adaac3cef4b",
  "docSlug": "1c626f0801e0e9ad1e805f8e0140c291",
  "documentTitle": "Alkermes | Results Presentation Deck | 26 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 26,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "cite_precedent",
  "function": "cite_precedent",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a screenshot of a medical journal article abstract to provide authority for the claims made in the bullet points.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e6c6-771e-b24a-5adaac3cef4b/5",
  "deckHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b",
  "deckJsonHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b.json",
  "deckAnchorHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.5,
        "y": 0.53
      },
      "kind": "framework",
      "text": "Interleukin-2 (IL-2) was historically one of the few treatment for adults with stage IV solid tumors that could produce complete responses that were often durable for decades without further therapy.",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2139d00-3d09-40b6-894b-e239d9289f5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.45,
        "x": 0.5,
        "y": 0.2
      },
      "kind": "image",
      "text": "Dutcher et al. Journal for ImmunoTherapy of Cancer 2014, 2:26. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014.",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3bdb5f1-5507-4a40-9c06-f9147b4cf850",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Interleukin-2 (IL-2) is a natural regulator of the activity of lymphocytes involved in the immune response. High-dose IL-2 (hdIL-2) monotherapy can drive complete and durable responses in certain tumor types, but its toxicity profile significantly limits its potential broader application. A molecule that recapitulates the anti-tumor activity of hdIL-2, without its hallmark toxicity issues, could be complementary to a wide range of other therapeutic approaches.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b0d076b-07e9-4521-baff-66d28573fb4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "High-Dose IL-2 Therapy Has Proven Anti-Tumor Efficacy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "415f2855-9eae-479c-a954-e27544ec61f3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "9c0958b8-e30e-4716-b2a3-bbee647b09f5",
      "evidence": "Uses a peer-reviewed journal abstract to validate the clinical efficacy of the therapy.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "742a23a6-bddc-4625-a92a-7f17683beece",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "Slides 5-6 discuss the limitations of current IL-2 therapies and the need for a new solution.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}